Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Linda Lundberg"'
Autor:
Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquín Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppa, Pauline Baumlin, Linda Lundberg, James Relf, Yuying Xie, Alessia Bottos, Kathryn Humphrey, Lorenzo Falchi
Publikováno v:
HemaSphere, Vol 7, p e458981a (2023)
Externí odkaz:
https://doaj.org/article/c4495cc7d2714f60818218c0cb6a1f50
Autor:
Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Krish Patel, Mark Hertzberg, Lorenzo Falchi, Nancy L. Bartlett, Joshua Brody, Linda Lundberg, Yuying Xie, Estefania Mulvihill, Pauline Baumlin, James Relf, Emily Piccione, Kathryn Humphrey, Michael Dickinson
Publikováno v:
Blood. 140:1062-1064
Autor:
Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Kathryn Humphrey, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Ben Byrne, Naseer Qayum, Carmelo Carlo-Stella
Publikováno v:
Blood. 140:178-180
Autor:
Michael J. Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Tomasz Wróbel, Fritz Offner, Marek Trněný, Shang-Ju Wu, Guillaume Cartron, Mark Hertzberg, Anna Sureda, David Perez-Callejo, Linda Lundberg, James Relf, Mark Dixon, Emma Clark, Kathryn Humphrey, Martin Hutchings
Publikováno v:
NEW ENGLAND JOURNAL OF MEDICINE
New England Journal of Medicine
New England Journal of Medicine, 2022, New England Journal of Medicine, 387, pp.2220-2231. ⟨10.1056/NEJMoa2206913⟩
New England Journal of Medicine
New England Journal of Medicine, 2022, New England Journal of Medicine, 387, pp.2220-2231. ⟨10.1056/NEJMoa2206913⟩
BackgroundThe prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells.MethodsIn the phase 2 part of a phase 1-2 study, we enrolled pati
Autor:
Artem Zharkov, Axel Boehnke, Christine McIntyre, Peter N. Morcos, Linda Lundberg, Ekaterina Gibiansky, Martin Barrett, Clarisse Chavanne, Nicolas Frey, Candice Jamois, Leonid Gibiansky
Publikováno v:
Clinical Pharmacology and Therapeutics
A fixed-dose subcutaneous (s.c.) formulation of the anti-CD20 antibody, rituximab, has been developed to address safety, infusion time, and patient comfort concerns relating to intravenous (i.v.) dosing, and has been approved based upon a pharmacokin
Autor:
Michael Crump, Anna Sureda Balari, Mark Dixon, David Carlile, Emily Piccione, Linda Lundberg, Michael Dickinson, Gloria Iacoboni, Martin Hutchings, Franck Morschhauser, Fritz Offner, James Relf, Emmanuel Bachy, Joaquin Martinez-Lopez, David Perez Callejo, Carmelo Carlo-Stella, Kathryn Humphrey
Publikováno v:
Blood. 136:46-48
Introduction : Glofitamab (RG6026) is a novel T-cell-engaging, bispecific, full-length antibody with a 2:1 molecular configuration that facilitates bivalent binding to CD20 on B-cells, and monovalent binding to CD3 on T-cells. Preclinically, glofitam
Autor:
Gloria Iacoboni, Anna Sureda, F. Morschhauser, Kathryn Humphrey, Martin Hutchings, Emma Clark, Michael Crump, Michael Dickinson, Emily Piccione, Carmelo Carlo-Stella, Corinne Haioun, James Relf, Emmanuel Bachy, Anton Belousov, David Carlile, Fritz Offner, Linda Lundberg, David Perez-Callejo
Publikováno v:
Hematological Oncology. 39
Autor:
Martin Weisser, Michael Dickinson, Gilles Salles, Michael Crump, Ann-Marie E Bröske, Peter N. Morcos, Carmelo Carlo-Stella, David Perez-Callejo, Natalie Dimier, Marina Bacac, Tom Moore, Franck Morschhauser, David Carlile, Denise Thomas, Cristiano Ferlini, Fritz Offner, Pablo Umana, Linda Lundberg, Martin Hutchings, Anton Belousov, Joaquin Martinez-Lopez, Gloria Iacoboni, Anna Sureda
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
Scientia
Dipòsit Digital de la UB
Universidad de Barcelona
Scientia
Dipòsit Digital de la UB
Universidad de Barcelona
PURPOSE Glofitamab is a T-cell–engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8809b1b8ec303d2f1340f2ad6f2994de
https://biblio.ugent.be/publication/8740332
https://biblio.ugent.be/publication/8740332
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Osman Ilhan, Stephan Stilgenbauer, Wolfgang Knauf, Thea Morris, Ekaterina Gresko, Eva Mikuskova, Linda Lundberg, Susan Robson, Eugen Tausch, Dariusz Woszczyk, Véronique Leblond, Francesc Bosch, Sebastian Böttcher, Tom Moore, Robin Foà, Christoph Renner
Publikováno v:
Leukemia
GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiv